Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference

FREMONT, Calif., Jan. 3, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, Jan. 10, 2018 at 10 a.m. PT. The conference is taking place Jan. 8-11, 2018 at the Westin St. Francis in San Francisco.

Ardelyx logo (PRNewsFoto/Ardelyx)

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor page of the Ardelyx website at Replays of the webcast will be available on the Ardelyx website for 60 days following the conference.

About Ardelyx, Inc.
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines. Ardelyx's cardiorenal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of hyperkalemia. In addition to its cardiorenal pipeline, Ardelyx has completed Phase 3 development of tenapanor for the treatment of people with irritable bowel syndrome with constipation and anticipates submitting a New Drug Application to the U.S. Food and Drug Administration for this indication in the second half of 2018. To efficiently bring its treatments to market, Ardelyx is pursing strategic collaborations in the U.S. and beyond, with established agreements with Fosun Pharma in China and Kyowa Hakko Kirin in Japan. For more information, please visit  and connect with us on Twitter @Ardelyx.


Cision View original content with multimedia:

SOURCE Ardelyx

Monique Allaire, THRUST IR, 781-631-0759, or Alicia Davis, THRUST IR, 910-620-3302,